Since upregulation of HER3 [6] and alterations in JAM-A [20] have been associated with the development of resistance to HER2-targeted therapies in breast cancer patients, this study aimed to uncover mechanisms of JAM-A/HER3 crosstalk. The gene discussed is ERBB3; the disease is breast carcinoma.